"Insulin, Long-Acting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
MeSH Number(s)
D06.472.699.587.200.300
D12.644.548.586.200.300
Below are MeSH descriptors whose meaning is more general than "Insulin, Long-Acting".
Below are MeSH descriptors whose meaning is more specific than "Insulin, Long-Acting".
This graph shows the total number of publications written about "Insulin, Long-Acting" by people in Harvard Catalyst Profiles by year, and whether "Insulin, Long-Acting" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 4 | 4 |
| 2010 | 1 | 3 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 2 | 3 |
Below are the most recent publications written about "Insulin, Long-Acting" by people in Profiles.
-
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab. 2021 11; 23(11):2572-2581.
-
Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching. PLoS Med. 2021 06; 18(6):e1003645.
-
Glycaemic control and hypoglycaemia risk with insulin glargine 300?U/mL and insulin degludec 100?U/mL in older participants in the BRIGHT trial. Diabetes Obes Metab. 2021 07; 23(7):1588-1593.
-
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes Obes Metab. 2020 11; 22(11):2170-2178.
-
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs. 2020 Feb; 80(2):147-165.
-
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100?units/mL at 26?weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. Diabetes Obes Metab. 2020 05; 22(5):873-878.
-
Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2019 Nov; 25(11):1162-1171.
-
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):596-605.
-
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. Diabetes Care. 2018 01; 41(1):39-48.
-
Diabetes in the Older Patient: A Role for C-Peptide? Am J Med. 2017 Dec; 130(12):e545.